[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2000265516A1 - Compositions and methods for inhibiting islet dysfunction and autoimmune disorders - Google Patents

Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Info

Publication number
AU2000265516A1
AU2000265516A1 AU2000265516A AU6551600A AU2000265516A1 AU 2000265516 A1 AU2000265516 A1 AU 2000265516A1 AU 2000265516 A AU2000265516 A AU 2000265516A AU 6551600 A AU6551600 A AU 6551600A AU 2000265516 A1 AU2000265516 A1 AU 2000265516A1
Authority
AU
Australia
Prior art keywords
compositions
methods
autoimmune disorders
islet dysfunction
inhibiting islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000265516A
Inventor
David J. Hill
Claude Remacle
Brigitte Reusens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAWSON HEALTH RESEARCH INSTITUTE
Universite Catholique de Louvain UCL
Original Assignee
LAWSON HEALTH RES INST
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAWSON HEALTH RES INST, Universite Catholique de Louvain UCL filed Critical LAWSON HEALTH RES INST
Publication of AU2000265516A1 publication Critical patent/AU2000265516A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2000265516A 2000-08-11 2000-08-11 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders Abandoned AU2000265516A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2000/000925 WO2002013813A1 (en) 2000-08-11 2000-08-11 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Publications (1)

Publication Number Publication Date
AU2000265516A1 true AU2000265516A1 (en) 2002-02-25

Family

ID=4143075

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2000265516A Abandoned AU2000265516A1 (en) 2000-08-11 2000-08-11 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
AU2001283739A Abandoned AU2001283739A1 (en) 2000-08-11 2001-08-09 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001283739A Abandoned AU2001283739A1 (en) 2000-08-11 2001-08-09 Compositions and methods for inhibiting islet dysfunction and autoimmune disorders

Country Status (5)

Country Link
US (1) US20030180345A1 (en)
EP (1) EP1309321A1 (en)
AU (2) AU2000265516A1 (en)
CA (1) CA2386985A1 (en)
WO (2) WO2002013813A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537865A1 (en) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Use of sulfur containing compounds and proteolytic enzymes for the prevention and therapy of the UDP-Glucuronosyltransferase 1 deficient Type II Diabetes mellitus
EP1537864A1 (en) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Use of amino acids and sulphur-containing compounds for the prevention and therapy of the UDP Glucuronosyltransferase 1 deficient Type II Diabetes mellitus
EP1715881A1 (en) * 2004-02-12 2006-11-02 Campina Nederland Holding B.V. Cysteine rich peptides for improving thiol homeostasis
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
CA2691147C (en) * 2006-07-28 2018-07-10 Mattia Locatelli Prediction and prophylactic treatment of type 1 diabetes
US20080026378A1 (en) 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
WO2014096843A2 (en) 2012-12-20 2014-06-26 Convatec Technologies Inc. Processing of chemically modified cellulosic fibres

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
SE8704542D0 (en) * 1987-11-19 1987-11-19 Draco Ab NEW DERIVATIVES OF CYSTEINE
ES2012958A6 (en) * 1988-01-25 1990-04-16 Santen Pharmaceutical Co Ltd Cysteine derivatives.
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US4980168A (en) * 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
RU2054936C1 (en) * 1994-04-07 1996-02-27 Елизарова Евгения Павловна Membrane-stabilizing agent for treatment of patient with insulin-dependent and insulin-independent diabetes mellitus
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US6171856B1 (en) * 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6136339A (en) * 1998-08-21 2000-10-24 Gardiner; Paul T. Food supplements and methods comprising lipoic acid and creatine
JP2000119179A (en) * 1998-10-09 2000-04-25 Taisho Pharmaceut Co Ltd Preventing agent for complication of non-insulin- dependent diabetes
IT1312377B1 (en) * 1999-03-05 2002-04-15 Uni Ci S R L COMPOSITIONS BASED ON TIOTIC ACID, CISTEIN AND / OR N-ACETYL CISTEINADA USE IN PHARMACEUTICAL, DIETETIC AND COSMETIC PREPARATIONS
WO2000072854A1 (en) * 1999-06-02 2000-12-07 Ashni Naturaceuticals, Inc. A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine

Also Published As

Publication number Publication date
WO2002013814A1 (en) 2002-02-21
AU2001283739A1 (en) 2002-02-25
US20030180345A1 (en) 2003-09-25
EP1309321A1 (en) 2003-05-14
WO2002013813A1 (en) 2002-02-21
CA2386985A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU2778801A (en) Antisense compositions and methods
AU2001245660A1 (en) Embolic compositions
AUPQ419099A0 (en) Novel compositions and methods
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
GB2351285B (en) Corrosion inhibiting compositions and methods
HUP0302772A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
EP1284723A4 (en) Compositions and therapies for hyperlipidaemia-associated disorders
AU4577999A (en) Methods and compositions for inhibiting corrosion
AU2001286750A1 (en) Compositions and methods for exon profiling
AU2001283739A1 (en) Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
AU2001244562A1 (en) Neovascularization inhibitors
AU2002239258A1 (en) Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2002351200A1 (en) Compositions and methods for inhibiting prenyltransferases
AU5632300A (en) Methods of inhibiting muscle atrophy
AU7330600A (en) Methods and compositions for the chromosomal integration of heterologous sequences
AU2641199A (en) Remedies for erectile dysfunction
AU2001251111A1 (en) Lubricant and flushing compositions
EP1221963A4 (en) Methods of inhibiting osteoclastogenesis
AU2001264650A1 (en) Adrenal dysfunction
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
AU2002228911A1 (en) Methods for inhibiting pain